Zoetis Inc. announced that the US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for Simparica Trio to treat infestations caused by New World screwworm (Cochliomyia hominivorax) larvae in dogs and puppies. This regulatory milestone provides veterinarians with a critical tool to address a parasite that feeds on living tissues and can cause severe damage or death if untreated.

The authorization comes as New World screwworm continues to threaten animal health in the US, prompting several states to issue formal orders requiring treatment of domestic animals moving from infested areas. Under the EUA framework, the FDA permits the use of medications in emergencies to treat life-threatening conditions when specific criteria are met.

Multi-Species Response Strategy

Zoetis is deploying a coordinated response across both companion animals and livestock sectors. While Simparica Trio targets dogs, the company also offers Dectomax-CA1 Injectable (doramectin injection) for cattle. This product holds conditional approval for preventing and treating NWS larvae infestations in beef cattle, female dairy cattle under 20 months of age, pregnant beef cows, newborn calves, and bulls.

Additionally, the FDA issued separate EUAs for Dectomax/Dectomax-CA1 for use in other species:

• Dairy cattle (lactating cows, dry cows, and heifers 20 months or older)
• Swine, sheep (excluding lactating sheep), and deer for prevention
• Horses aged 1 year or older for prevention

Simparica Trio remains FDA-approved for its standard indications, including prevention of heartworm disease and control of ticks, fleas, roundworms, and hookworms. It is indicated for dogs and puppies 8 weeks of age and older weighing 2.8 pounds or greater.

Regulatory and Safety Considerations

The EUA for Simparica Trio is valid only for the duration of the emergency declaration under Section 564(b)(1) of the Federal Food, Drug, and Cosmetic Act. The product is not fully approved for this specific use.

Safety data indicates that Simparica Trio contains sarolaner, an isoxazoline associated with neurologic adverse reactions such as tremors, ataxia, and seizures in dogs with or without a history of neurologic disorders. Use requires caution in dogs with a seizure history. The most frequently reported adverse reactions in clinical trials were vomiting and diarrhea. Safe use has not been evaluated in breeding, pregnant, or lactating dogs.

For livestock treatments, withdrawal periods apply. Dectomax-CA1 requires a 35-day pre-slaughter withdrawal period for cattle, sheep, and deer, and a 24-day period for swine. Milk from dairy cattle must be withheld for 468 hours (19.5 days) after treatment ends.

William Blair analyst Brandon Vazquez has downgraded Zoetis (NYSE: ZTS) from an Outperform rating to Market Perform. The downgrade signals a more neutral stance from the investment bank regarding the animal health company's near-term prospects, moving away from its previous bullish recommendation.

Rating Change Details

The rating adjustment was executed by Brandon Vazquez, an analyst at William Blair. Previously, the firm held Zoetis at an Outperform rating, indicating that the stock was expected to outperform its peer group or benchmark. The new Market Perform rating suggests that Zoetis is expected to perform in line with the broader market or sector average.

Implications for Investors

The shift to a Market Perform rating typically implies that investors should expect returns consistent with the market index rather than excess alpha. While the source document does not detail the specific financial drivers or valuation metrics behind this decision, such downgrades often stem from concerns regarding growth visibility, margin pressure, or relative valuation compared to peers.

Investors monitoring Zoetis should consider this change as part of their broader due diligence process. The absence of specific price targets or detailed rationale in the initial report necessitates further review of William Blair’s full research note for comprehensive context on the firm's reasoning.